Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Dec 5, 2025

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels –    – Positive outcomes for dialysis patients suffering from Steal syndrome who were treated with the ATEV – – Additional presentations report durable two-year outcomes for patients treated in Ukraine conflict, superior two-year outcomes for female dialysis patients, and results for patients treated with torso arterial trauma – DURHAM, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced highlights of five podium presentations on the Company's acellular tissue engineered vessel (ATEV™) made yesterday at the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques And Horizons (VEITHsymposium), in New York, NY.

GlobeNewsWire • Nov 20, 2025

Should You Invest in Humacyte, Inc. (HUMA) Based on Bullish Wall Street Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • Nov 14, 2025

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six presentations on the Company's acellular tissue engineered vessel (ATEV™) that are scheduled for the 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques And Horizons (VEITHsymposium), to be held November 18-22, 2025 in New York, NY.

GlobeNewsWire • Nov 13, 2025

Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript

Humacyte, Inc. ( HUMA ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Laura Niklason - Founder, President, CEO & Director Dale Sander - CFO, Chief Corporate Development Officer & Treasurer Conference Call Participants Thomas Johnson - Lifesci Advisors, LLC Sneha Muthe - Barclays Bank PLC, Research Division Iseult McMahon - BTIG, LLC, Research Division Joshua Jennings - TD Cowen, Research Division Jason Kolbert - D. Boral Capital LLC, Research Division Bruce Jackson - The Benchmark Company, LLC, Research Division Swayampakula Ramakanth - H.C.

Seeking Alpha • Nov 12, 2025

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement -  - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations - - Conference call today at 8:00 am ET - DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.

GlobeNewsWire • Nov 12, 2025

Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.33 per share a year ago.

Zacks Investment Research • Nov 12, 2025

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer duration of ATEV use in these high-need patients could greatly reduce reliance on catheters for dialysis access, a major cause of complications, morbidity and cost in dialysis patients – DURHAM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of positive two-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous (AV) access for hemodialysis patients at the American Society of Nephrology's (ASN) Kidney Week 2025, the premier nephrology meeting, in Houston.

GlobeNewsWire • Nov 10, 2025

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.

GlobeNewsWire • Nov 6, 2025

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.31, representing a -10% change from its previous close.

Zacks Investment Research • Nov 7, 2025